We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will ...

Harrow is a fast-growing ophthalmic pharma company focused on delivering eye care drugs. Click here to read more about HROW's ...

Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...

Eyecare pharmaceutical company Harrow Health is expanding its Nashville corporate headquarters in a $3 million investment that is slated to bring 147 new jobs to the city. Harrow announced the move ...